ArticleJournal of medical virology2025
Seroprevalence and Placental Transfer of Zika and Dengue Virus Antibodies in Postpartum Women in Southeast Brazil.
Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Zika (ZIKV) and dengue (DENV) viruses are major public health concerns in Brazil. Understanding population serological status, particularly in pregnant women, is vital for estimating their spread. This study assessed ZIKV and DENV seroprevalence in pregnant women and the transplacental transfer of antibodies to their newborns, crucial for early-life protection. A cross-sectional seroprevalence study was conducted with 601 postpartum women and their newborns in São Paulo city, Brazil post-ZIKV fever outbreak. Paired maternal and umbilical blood samples were collected for ZIKV and DENV antibody testing, which was conducted using ELISA and virus neutralization tests. Maternal and neonatal sociodemographic and clinical data were obtained from interviews and medical records. ZIKV and DENV neutralizing antibodies (nAbs) were detected in 2.4% and 31.6% of participants, respectively. Maternal place of birth, parity, education level, and prenatal Toxoplasmosis serology were identified as risk factors associated with ZIKV and/or DENV infection. Effective transplacental transfer of specific ZIKV and DENV antibodies from mothers to newborns was observed. Nulliparous women and those with a history of DENV infection exhibited higher transfer ratios (TR) of DENV antibodies. Low-birthweight and preterm neonates had lower DENV-1 antibody TRs than heavier and term infants. Low seroprevalence of ZIKV and DENV antibodies in the study population indicates a high vulnerability to infection by these viruses. Maternal and neonatal characteristics were associated with seropositivity for ZIKV and DENV and the efficiency of DENV antibody transfer to neonates. These findings can guide public health strategies for evaluating the TR effectiveness of antibodies following future ZIKV and DENV vaccination programs in pregnant women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.